Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

Neurology Neuroimmunology & Neuroinflammation 2026 Open access

Read full text
Authors: Tanuja Chitnis, Tarun Singhal, Jonathan Zurawski, Taylor J. Saraceno, Niveditha Gopalakrishnan, Lauren E. Cain, Brenna A. LaBarre, D. A. King, Regan W. Bergmark, Alice Z. Maxfield, Steven Cicero, Hong Pan
+14 more Shipra Dubey, Steven Vaquerano, Caleb Hansel, B.F Healy, Shrishti Saxena, Hrishikesh A. Lokhande, Moogeh Baharnoori, Evan Madill, Manali Shah Sheth, Rachel Rodin, Jessica Ye, Nancy Clementi, William A. Clementi, Howard L. Weiner
DOI: 10.1212/nxi.0000000000200543
Cited by: 2
References: 43

Abstract

Progression independent of relapses (PIRA) is a major therapeutic challenge in multiple sclerosis (MS). Nasal anti-CD3 treats animal models of progressive MS by inducing regulatory T cells (Tregs) that suppress CNS inflammation and lessen clinical disease.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Advanced Drug Delivery Systems Immunotherapy and Immune Responses

Publication details

Journal / source
Neurology Neuroimmunology & Neuroinflammation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
13
Issue
2
Publication date
16 January 2026
Language
EN